statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stifel Nicolaus Remains a Buy on IQVIA Holdings (IQV)

In a report released yesterday, Shlomo Rosenbaum from Stifel Nicolaus maintained a Buy rating on IQVIA Holdings (IQV Research Report), with a pri...

IQVIA Holdings Outperforms with Strong Q2 Results and Positive Growth Outlook: Cherny Maintains Buy Rating

Analyst Michael Cherny of Leerink Partners reiterated a Buy rating on IQVIA Holdings (IQV Research Report), reducing the price target to $270.00...

Barclays Sticks to Its Buy Rating for IQVIA Holdings (IQV)

In a report released today, Luke Sergott from Barclays maintained a Buy rating on IQVIA Holdings (IQV Research Report), with a price target of $2...

IQVIA Holdings: Strong H2 Outlook with Buoyant TAS, RWE, and RDS Segments Driving Buy Rating

TD Cowen analyst Charles Rhyee maintained a Buy rating on IQVIA Holdings (IQV Research Report) yesterday and set a price target of $270.00. Charl...

IQVIA Holdings Inc, on Monday, reported an upbeat set of earnings that topped Wall Street estimates while also raising its revenue and earnings per share (EPS) guidance for 2024. Following the announcement, shares of the firm jumped nearly 7% and retail sentiment entered extremely bullish territory (76/100) from a neutral zone supported by extremely high message volumes.<figure class="image"><img style="aspect-ratio:795/228;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_22_at_3_09_52_PM_e9a57ca2e1.png" alt="Retail sentiment trends in extremely bullish territory for IQVIA Holdings" width="795" height="228"><figcaption>Retail sentiment trends in extremely bullish territory for IQVIA Holdings</figcaption></figure>The firm, which provides advanced analytics, technology solutions, and clinical research services to the life sciences industry, reported a 2.30% year-over-year (YoY) rise in its second quarter revenue at $3.81 billion which stood higher than a Street estimate of $3.79 billion. Net income rose 22% YoY to $363 million during the quarter. The firm reported an adjusted diluted EPS of $2.64 as compared to a Street estimate of $2.57.IQVIA Holdings pointed out that as of June 30, 2024, Research &amp; Development Solutions (R&amp;DS) contracted backlog (including reimbursed expenses), stood at $30.60 billion–growing 7.70% year-over-year and 8.10% at constant currency. The company said it expects approximately $7.80 billion of this backlog to convert to revenue in the next twelve months.Ari Bousbib, chairman and CEO of IQVIA said the firm delivered second quarter results at the high-end of its guidance, driven mainly by better-than-expected Technology &amp; Analytics Solutions (TAS) performance. TAS revenue came in at $1.49 billion, registering an increase of 2.70% on a reported basis and 3.80% on a constant currency basis.The company has updated its full-year 2024 guidance for revenue to be between $15.43 billion and $15.53 billion, as compared to an earlier guidance of $15.33-15.58 billion. Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) is expected between $3.71 billion and $3.77 billion, compared with an earlier guidance of $3.70-3.80. Adjusted diluted EPS is estimated between $11.10 and $11.30 compared with an earlier guidance of $10.95-11.25.One Stocktwits user named ‘Wigglyick’ has expressed optimism on the technical pattern formed by the stock, which other users cited as evidence of its improving fundamental picture.<figure class="image"><a href="https://stocktwits.com/Wigglyick"><img style="aspect-ratio:784/612;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_22_at_3_11_34_PM_d36f6ac6b2.png" alt="Stocktwits user Wigglyick's post on IQVIA Holdings" width="784" height="612"></a><figcaption>Stocktwits user Wigglyick's post on IQVIA Holdings</figcaption></figure> &nbsp;

Retail Raves About IQVIA Holdings After Firm Raises Revenue, Profit Guidance

IQVIA Holdings has updated its full-year 2024 guidance for revenue to be between $15.43 billion and $15.53 billion, as compared to an earlier guidance of $15.33-$15.58 billion. 

Equity

IQVIA Holdings has updated its full-year 2024 guidance for revenue to be between $15.43 billion and $15.53 billion, as compared to an earlier guidance of $15.33-$15.58 billion. Retail sentiment entered extremely bullish territory (77/100) from a neutral zone supported by extremely high message volumes.

IQVIA Stock Pops After It Beats Q2 Earnings Estimates

Igor Golovniov / SOPA Images / LightRocket via Getty Images

 Key TakeawaysLife sciences clinical researcher IQVIA's second-quarter results beat analysts' expectations for revenue and net...

IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings

IQVIA Holdings Inc (NASDAQ:IQV) reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.

 Latest Ratings for IQV
 DateFirmActionFromTo Mar 2022MizuhoMaintainsBuy Feb...

IQVIA Reports Second-Quarter 2024 Results

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial...

IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group

IQVIA (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix...

IQVIA to Announce Second-Quarter 2024 Results on July 22, 2024

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference...

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Volume	1.2M
52-Wk High	$261.73
52-Wk Low	$167.42

IQV IQVIA Holdings Inc

About

Feed

News

Sentiment

Earnings

Fundamentals